Project Overview

Project Type: Greater Health

Project Location: Guangzhou

Product Series:

Homogeneous series

Guangzhou Qianhai Life Insurance General Hospital

Qianhai Life Guangzhou General Hospital is a Grade-III comprehensive hospital wholly funded and constructed by Qianhai Life Insurance Co., Ltd. Located at No. 703 Xincheng Avenue, Zengcheng District, Guangzhou City, it officially began operations in October 2019. The hospital covers an area of 98,000 square meters and is designed to accommodate 1,800 beds, with more than 40 clinical departments. It places particular emphasis on developing specialized fields such as neurology, digestive diseases, cardiovascular medicine, and oncology. The hospital is equipped with cutting-edge medical technologies, including PET-CT, Gamma Knife, and a proton therapy system, and has also established an outpatient clinic in Zhujiang New Town, Tianhe District. Currently, the hospital’s president, Wang Jianping, is a renowned expert in general surgery. The hospital employs a total of 1,162 staff members, including 122 professionals holding master’s or doctoral degrees, and boasts 22 faculty members serving as doctoral or master’s supervisors. 
As a key investment attraction project in Zengcheng District, the hospital is being constructed to meet the standards of a Grade-III medical facility, integrating medical care, research, education, and wellness services under one roof. The second through fourth phases of the project include plans for a proton therapy center specializing in oncology, as well as comprehensive health and wellness initiatives, alongside the establishment of six distinctive clinical centers, such as a Neurology Medical Center. The hospital also plays a vital role in regional emergency care and preventive healthcare, pioneering several cutting-edge diagnostic and treatment techniques unique to the area. It has earned prestigious national certifications, including recognition as a National Chest Pain Center. During the pandemic, the hospital successfully completed nucleic acid sampling for nearly 4 million people. As of 2024, the hospital has provided outpatient services to nearly 3 million patient visits and treated over 100,000 inpatients.